Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date
Ami B Patel, Joohi Jimenez-Shahed Department of Neurology, Baylor College of Medicine, Houston, TX, USA Abstract: Inhaled levodopa is a newly emerging therapeutic option in the treatment of “off” symptoms associated with Parkinson’s disease (PD). Its mode of...
Guardado en:
Autores principales: | Patel AB, Jimenez-Shahed J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9aebef3e7e3e4cf0ab7f3e16661e4c13 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Werner Poewe, et al.
Publicado: (2010) -
Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser RA, et al.
Publicado: (2018) -
Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease
por: Daniel D Truong
Publicado: (2009) -
Understanding the Importance of Capsules in Dry Powder Inhalers
por: Francesca Buttini, et al.
Publicado: (2021) -
The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
por: Wu N, et al.
Publicado: (2018)